(19)
(11) EP 4 770 634 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24861013.1

(22) Date of filing: 29.08.2024
(51) International Patent Classification (IPC): 
A61K 31/395(2006.01)
A61K 31/426(2006.01)
 A61K 31/44(2006.01)
A61K 31/33(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/426; A61K 31/4439; A61K 31/427; A61K 31/506; A61K 31/517
(86) International application number:
PCT/US2024/044377
(87) International publication number:
WO 2025/049710 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 29.08.2023 US 202363535192 P

(71) Applicant: Aclipse Two Inc.
Radnor, PA 19087 (US)

(72) Inventor:
  • SHAN, Ning
    Chandler, Arizona 85249 (US)

(74) Representative: Herrero & Asociados, S.L. 
Edificio Aqua - Calle Agustín de Foxá, 4-10, 2ºA
28036 Madrid
28036 Madrid (ES)

   


(54) PHARMACEUTICAL COMPOSITION FOR USE IN THE DISEASE TREATMENTS